Alcon Science Resource Library

Valeda Photobiomodulation: Mechanism of Action

In this video, Zarmeena Vendal, MD, presents: "Clinical Effect of the Addition of Netarsudil 0.02% Vs Brimonidine 0.1% in Normal Tension Glaucoma Patients Currently on Latanoprost 0.005%".

In this video, David L. Wirta, MD, presents: "Tear Volume and Tear Total Lipid Concentration Following Administration of Acoltremon 0.003%".

In this video, Eric Jennings, MD, presents "Visual outcomes of spherical monofocal IOL implantation using the cloud-based SMARTCataract surgical planning platform"

Cataract surgeons historically had to operate at higher infusion pressures to allow for adequate anterior chamber stability with efficient aspiration flow rates and vacuum. Higher pressures helped to compensate for dynamic…

At Alcon, our surgical medical device products, such as the PanOptix® Trifocal IOL, are designed, manufactured and marketed with a body of science developed through rigorous bench research and clinical studies. As the body of…

Watch this Clinical Study video: Evolving First-Line Glaucoma Treatment: Directive Selective Laser Trabeculoplasty (DSLT)

A roundtable discussion exploring Rho kinase inhibitors that target the conventional outflow pathway.

Data from the pivotal COMET clinical trials reveal how the first topical ocular neuromodulator approved for DED—TRYPTYR (acoltremon ophthalmic solution) 0.003%—delivers a rapid and lasting increase in natural tear production.…